J. D. Burton, R. N. Bamford, C. Peters, A. J. Grant, G. Kurys et al., A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells., Proceedings of the National Academy of Sciences, vol.91, issue.11, pp.4935-4939, 1994.

K. H. Grabstein, J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan et al., Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor, Science, vol.264, issue.5161, pp.965-968, 1994.

T. A. Waldmann, Interleukin-15 in the treatment of cancer, Expert Review of Clinical Immunology, vol.10, issue.12, pp.1689-1701, 2014.

T. A. Fehniger and M. A. Caligiuri, Interleukin 15: biology and relevance to human disease, Blood, vol.97, issue.1, pp.14-32, 2001.

B. G. Anderson and L. S. Quinn, Free IL-15 Is More Abundant Than IL-15 Complexed With Soluble IL-15 Receptor-? in Murine Serum: Implications for the Mechanism of IL-15 Secretion, Endocrinology, vol.157, issue.3, pp.1315-1320, 2016.

W. E. Carson, J. G. Giri, M. J. Lindemann, M. L. Linett, M. Ahdieh et al., Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor., Journal of Experimental Medicine, vol.180, issue.4, pp.1395-1403, 1994.

D. M. Anderson, S. Kumaki, and M. Ahdieh, Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes, J Biol Chem, vol.270, pp.29862-29871, 1995.

R. Pereno, J. Giron-michel, A. Gaggero, E. Cazes, R. Meazza et al., IL-15/IL-15R? intracellular trafficking in human melanoma cells and signal transduction through the IL-15R?, Oncogene, vol.19, issue.45, pp.5153-5162, 2000.

T. A. Waldmann, The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design, Nature Reviews Immunology, vol.6, issue.8, pp.595-601, 2006.

M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal et al., Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens, Journal of Clinical Oncology, vol.26, issue.32, pp.5233-5239, 2008.

M. Boyiadzis, S. Memon, J. Carson, K. Allen, M. J. Szczepanski et al., Up-regulation of NK Cell Activating Receptors Following Allogeneic Hematopoietic Stem Cell Transplantation under a Lymphodepleting Reduced Intensity Regimen is Associated with Elevated IL-15 Levels, Biology of Blood and Marrow Transplantation, vol.14, issue.3, pp.290-300, 2008.

L. Gattinoni, S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer et al., Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells, Journal of Experimental Medicine, vol.202, issue.7, pp.907-912, 2005.

S. M. Anthony, S. C. Rivas, S. L. Colpitts, M. E. Howard, S. W. Stonier et al., Inflammatory Signals Regulate IL-15 in Response to Lymphodepletion, The Journal of Immunology, vol.196, issue.11, pp.4544-4552, 2016.

J. Giron-michel, M. Giuliani, M. Fogli, D. Brouty-boye?, S. Ferrini et al., Membrane-bound and soluble IL-15/IL-15R? complexes display differential signaling and functions on human hematopoietic progenitors, Blood, vol.106, issue.7, pp.2302-2310, 2005.

E. Mortier, A. Quéméner, P. Vusio, I. Lorenzen, Y. Boublik et al., Soluble Interleukin-15 Receptor ? (IL-15R?)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15R?/?, Journal of Biological Chemistry, vol.281, issue.3, pp.1612-1619, 2005.

F. Tamzalit, I. Barbieux, A. Plet, J. Heim, S. Nedellec et al., IL-15.IL-15R complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells, Proceedings of the National Academy of Sciences, vol.111, issue.23, pp.8565-8570, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02437298

M. P. Rubinstein, M. Kovar, J. F. Purton, J. Cho, O. Boyman et al., Converting IL-15 to a superagonist by binding to soluble IL-15R, Proceedings of the National Academy of Sciences, vol.103, issue.24, pp.9166-9171, 2006.

T. A. Stoklasek, K. S. Schluns, and L. Lefrançois, Combined IL-15/IL-15R? Immunotherapy Maximizes IL-15 Activity In Vivo, The Journal of Immunology, vol.177, issue.9, pp.6072-6080, 2006.

S. Dubois, J. Mariner, T. A. Waldmann, and Y. Tagaya, IL-15R? Recycles and Presents IL-15 In trans to Neighboring Cells, Immunity, vol.17, issue.5, pp.537-547, 2002.

S. Bulfone-paus, E. Bulanova, V. Budagian, and R. Paus, The interleukin-15/interleukin-15 receptor system as a model for juxtacrine and reverse signaling, BioEssays, vol.28, issue.4, pp.362-377, 2006.

G. G. Neely, S. Epelman, L. L. Ma, P. Colarusso, C. J. Howlett et al., Monocyte Surface-Bound IL-15 Can Function as an Activating Receptor and Participate in Reverse Signaling, The Journal of Immunology, vol.172, issue.7, pp.4225-4234, 2004.

H. Bo, X. Wei, H. Dong, Y. Zhang, P. Lv et al., Elevated Expression of Transmembrane IL-15 in Immune Cells Correlates with the Development of Murine Lupus: a Potential Target for Immunotherapy Against SLE, Scandinavian Journal of Immunology, vol.69, issue.2, pp.119-129, 2009.

S. K. Olsen, N. Ota, S. Kishishita, M. Kukimoto-niino, K. Murayama et al., Crystal Structure of the Interleukin-15·Interleukin-15 Receptor ? Complex, Journal of Biological Chemistry, vol.282, issue.51, pp.37191-37204, 2007.

P. R. Burkett, R. Koka, M. Chien, S. Chai, D. L. Boone et al., Coordinate Expression and Trans Presentation of Interleukin (IL)-15R? and IL-15 Supports Natural Killer Cell and Memory CD8+ T Cell Homeostasis, Journal of Experimental Medicine, vol.200, issue.7, pp.825-834, 2004.

E. Mortier, R. Advincula, and L. Kim, Macrophage-and dendriticcell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets, Cancer Res, vol.31, pp.1561-1570, 2009.

H. Perdreau, E. Mortier, G. Bouchaud, V. Solé, Y. Boublik et al., PS1-57 Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation, Cytokine, vol.52, issue.1-2, p.29, 2010.

G. Bouchaud, E. Mortier, M. Flamant, I. Barbieux, A. Plet et al., Interleukin-15 and Its Soluble Receptor Mediate the Response to Infliximab in Patients With Crohn's Disease, Gastroenterology, vol.138, issue.7, pp.2378-2387, 2010.

C. Bergamaschi, J. Bear, M. Rosati, R. K. Beach, C. Alicea et al., Circulating IL-15 exists as heterodimeric complex with soluble IL-15R? in human and mouse serum, Blood, vol.120, issue.1, pp.e1-e8, 2012.

L. S. Quinn, B. G. Anderson, L. Strait-bodey, and T. Wolden-hanson, Serum and muscle interleukin-15 levels decrease in aging mice: Correlation with declines in soluble interleukin-15 receptor alpha expression, Experimental Gerontology, vol.45, issue.2, pp.106-112, 2010.

A. Lamana, A. M. Ortiz, and J. M. Alvaro-gracia, Characterization of serum interleukin-15 in healthy volunteers and patients with early arthritis to assess its potential use as a biomarker, Eur Cytokine Netw, vol.21, pp.186-94, 2010.

J. Suzuki, S. Morimoto, and H. Amano, Serum levels of interleukin 15 in patients with rheumatic diseases, J Rheumatol, vol.28, pp.2389-91, 2001.

S. Kakumu, A. Okumura, T. Ishikawa, M. Yano, A. Enomoto et al., Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-?) receptors in type C chronic liver disease, Clinical & Experimental Immunology, vol.109, issue.3, pp.458-463, 1997.

S. Gangemi, G. Basile, D. Monti, R. A. Merendino, G. D. Pasquale et al., Age-Related Modifications in Circulating IL-15 Levels in Humans, Mediators of Inflammation, vol.2005, issue.4, pp.245-247, 2005.

S. M. Anthony, M. E. Howard, Y. Hailemichael, W. W. Overwijk, and K. S. Schluns, Soluble Interleukin-15 Complexes Are Generated In Vivo by Type I Interferon Dependent and Independent Pathways, PLOS ONE, vol.10, issue.3, p.e0120274, 2015.

J. Chen, M. Petrus, R. Bamford, J. H. Shih, J. C. Morris et al., Increased serum soluble IL-15R? levels in T-cell large granular lymphocyte leukemia, Blood, vol.119, issue.1, pp.137-143, 2012.

S. Dubois, F. Magrangeas, P. Lehours, S. Raher, J. Bernard et al., Natural Splicing of Exon 2 of Human Interleukin-15 Receptor ?-Chain mRNA Results in a Shortened Form with a Distinct Pattern of Expression, Journal of Biological Chemistry, vol.274, issue.38, pp.26978-26984, 1999.

E. Mortier, J. Bernard, A. Plet, and Y. Jacques, Natural, Proteolytic Release of a Soluble Form of Human IL-15 Receptor ?-Chain That Behaves as a Specific, High Affinity IL-15 Antagonist, The Journal of Immunology, vol.173, issue.3, pp.1681-1688, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-02437358

C. Badoual, G. Bouchaud, N. E. Agueznay, E. Mortier, S. Hans et al., The Soluble Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer, Cancer Research, vol.68, issue.10, pp.3907-3914, 2008.
URL : https://hal.archives-ouvertes.fr/hal-01679874

J. R. Müller, T. A. Waldmann, M. J. Kruhlak, and S. Dubois, Paracrine and Transpresentation Functions of IL-15 Are Mediated by Diverse Splice Versions of IL-15R? in Human Monocytes and Dendritic Cells, Journal of Biological Chemistry, vol.287, issue.48, pp.40328-40338, 2012.

R. Zambello, M. Facco, L. Trentin, R. Sancetta, C. Tassinari et al., Interleukin-15 Triggers the Proliferation and Cytotoxicity of Granular Lymphocytes in Patients With Lymphoproliferative Disease of Granular Lymphocytes, Blood, vol.89, issue.1, pp.201-211, 1997.

U. Do?bbeling, R. Dummer, E. Laine, N. Potoczna, J. Qin et al., Interleukin-15 Is an Autocrine/Paracrine Viability Factor for Cutaneous T-Cell Lymphoma Cells, Blood, vol.92, issue.1, pp.252-258, 1998.

N. Azimi, K. Brown, R. N. Bamford, Y. Tagaya, U. Siebenlist et al., Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF- B site, Proceedings of the National Academy of Sciences, vol.95, issue.5, pp.2452-2457, 1998.

J. M. Mariner, V. Lantz, T. A. Waldmann, and N. Azimi, Human T Cell Lymphotropic Virus Type I Tax Activates IL-15R? Gene Expression Through an NF-?B Site, The Journal of Immunology, vol.166, issue.4, pp.2602-2609, 2001.

I. Tinhofer, I. Marschitz, T. Henn, A. Egle, and R. Greil, Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma, Blood, vol.95, issue.2, pp.610-618, 2000.

S. T. Nguyen, S. Hasegawa, H. Tsuda, H. Tomioka, M. Ushijima et al., Identification of a predictive gene expression signature of cervical lymph node metastasis in oral squamous cell carcinoma, Cancer Science, vol.98, issue.5, pp.740-746, 2007.

M. Seike, N. Yanaihara, E. D. Bowman, K. A. Zanetti, A. Budhu et al., Use of a Cytokine Gene Expression Signature in Lung Adenocarcinoma and the Surrounding Tissue as a Prognostic Classifier, JNCI: Journal of the National Cancer Institute, vol.99, issue.16, pp.1257-1269, 2007.

C. Barzegar, R. Meazza, R. Pereno, C. Pottin-clemenceau, M. Scudeletti et al., IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops, Oncogene, vol.16, issue.19, pp.2503-2512, 1998.

C. Doucet, R. Meazza, C. Pottin-clemenceau, M. Scudeletti, D. Brouty-boye et al., Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient, Melanoma Research, vol.7, issue.SUPPLEMENT 2, p.S19, 1997.

R. M. Santana-carrero, F. Beceren-braun, S. C. Rivas, S. M. Hegde, A. Gangadharan et al., IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses, Proceedings of the National Academy of Sciences, vol.116, issue.2, pp.599-608, 2018.

P. Marra, S. Mathew, A. Grigoriadis, Y. Wu, F. Kyle-cezar et al., IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers, Cancer Research, vol.74, issue.17, pp.4908-4921, 2014.

J. Giron-michel, S. Azzi, S. Ferrini, S. Chouaib, G. Camussi et al., Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis, Cytokine & Growth Factor Reviews, vol.24, issue.1, pp.13-22, 2013.

S. Azzi, C. Gallerne, C. Romei, V. Le-coz, R. Gangemi et al., Human Renal Normal, Tumoral, and Cancer Stem Cells Express Membrane-Bound Interleukin-15 Isoforms Displaying Different Functions, Neoplasia, vol.17, issue.6, pp.509-517, 2015.

H. Yuan, X. Meng, W. Guo, P. Cai, W. Li et al., Transmembrane-Bound IL-15?Promoted Epithelial-Mesenchymal Transition in Renal Cancer Cells Requires the Src-Dependent Akt/GSK-3?/?-Catenin Pathway, Neoplasia, vol.17, issue.5, pp.410-420, 2015.

J. Giron-michel, S. Azzi, K. Khawam, E. Mortier, A. Caignard et al., Interleukin-15 Plays a Central Role in Human Kidney Physiology and Cancer through the ?c Signaling Pathway, PLoS ONE, vol.7, issue.2, p.e31624, 2012.

S. Azzi, S. Bruno, J. Giron-michel, D. Clay, A. Devocelle et al., Differentiation Therapy: Targeting Human Renal Cancer Stem Cells with Interleukin 15, JNCI: Journal of the National Cancer Institute, vol.103, issue.24, pp.1884-1898, 2011.

D. L. Blum, T. Koyama, A. E. M'koma, J. M. Iturregui, M. Martinez-ferrer et al., Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy, Clinical Cancer Research, vol.14, issue.23, pp.7790-7797, 2008.

K. Rohena-rivera, M. M. Sánchez-vázquez, D. A. Aponte-colón, I. S. Forestier-román, M. E. Quintero-aguiló et al., IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer, PLOS ONE, vol.12, issue.4, p.e0172786, 2017.

H. Kuniyasu, K. Yoshida, T. Sasaki, T. Sasahira, K. Fujii et al., Conjugated linoleic acid inhibits peritoneal metastasis in human gastrointestinal cancer cells, International Journal of Cancer, vol.118, issue.3, pp.571-576, 2005.

H. Kuniyasu, N. Oue, D. Nakae, M. Tsutsumi, A. Denda et al., Interleukin-15 Expression Is Associated with Malignant Potential in Colon Cancer Cells, Pathobiology, vol.69, issue.2, pp.86-95, 2001.

B. Mlecnik, G. Bindea, H. K. Angell, M. S. Sasso, A. C. Obenauf et al., Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients, Science Translational Medicine, vol.6, issue.228, pp.228ra37-228ra37, 2014.

A. Ahmad, R. Ahmad, A. Iannello, E. Toma, R. Morisset et al., IL-15 and HIV Infection: Lessons for Immunotherapy and Vaccination, Current HIV Research, vol.3, issue.3, pp.261-270, 2005.

A. Diab, A. D. Cohen, O. Alpdogan, and M. Perales, IL-15: targeting CD8+ T cells for immunotherapy, Cytotherapy, vol.7, issue.1, pp.23-35, 2005.

C. A. Klebanoff, L. Gattinoni, D. C. Palmer, P. Muranski, Y. Ji et al., Determinants of Successful CD8 + T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice, Clinical Cancer Research, vol.17, issue.16, pp.5343-5352, 2011.

P. Yu, J. C. Steel, M. Zhang, J. C. Morris, and T. A. Waldmann, Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model, Clinical Cancer Research, vol.16, issue.24, pp.6019-6028, 2010.

M. Zhang, Z. Yao, S. Dubois, W. Ju, J. R. Muller et al., Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer, Proceedings of the National Academy of Sciences, vol.106, issue.18, pp.7513-7518, 2009.

M. Vera, N. Razquin, J. Prieto, I. Melero, P. Fortes et al., Intratumoral Injection of Dendritic Cells Transduced by an SV40-Based Vector Expressing Interleukin-15 Induces Curative Immunity Mediated by CD8+ T Lymphocytes and NK Cells, Molecular Therapy, vol.12, issue.5, pp.950-959, 2005.

C. Bergamaschi, H. Pandit, B. A. Nagy, D. Stellas, S. M. Jensen et al., Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-?, CXCL9 and CXCL10, Journal for ImmunoTherapy of Cancer, vol.8, issue.1, p.e000599, 2020.

A. Bessard, V. Sole, G. Bouchaud, A. Quemener, and Y. Jacques, High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor fusion protein, in metastatic melanoma and colorectal cancer, Molecular Cancer Therapeutics, vol.8, issue.9, pp.2736-2745, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-02440759

Y. Guo, L. Luan, W. Rabacal, J. K. Bohannon, B. A. Fensterheim et al., IL-15 Superagonist?Mediated Immunotoxicity: Role of NK Cells and IFN-?, The Journal of Immunology, vol.195, issue.5, pp.2353-2364, 2015.

M. Desbois, C. Béal, M. Charrier, B. Besse, G. Meurice et al., IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment, Journal for ImmunoTherapy of Cancer, vol.8, issue.1, p.e000632, 2020.

M. Desbois, P. Le-vu, C. Coutzac, E. Marcheteau, C. Béal et al., IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists, The Journal of Immunology, vol.197, issue.1, pp.168-178, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01823361

E. Chertova, C. Bergamaschi, O. Chertov, R. Sowder, J. Bear et al., Characterization and Favorablein VivoProperties of Heterodimeric Soluble IL-15·IL-15R? Cytokine Compared to IL-15 Monomer, Journal of Biological Chemistry, vol.288, issue.25, pp.18093-18103, 2013.

S. S. Ng, B. A. Nagy, S. M. Jensen, X. Hu, C. Alicea et al., Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion, Clinical Cancer Research, vol.23, issue.11, pp.2817-2830, 2016.

N. K. Patil, L. Luan, J. K. Bohannon, Y. Guo, A. Hernandez et al., IL-15 Superagonist Expands mCD8+ T, NK and NKT Cells after Burn Injury but Fails to Improve Outcome during Burn Wound Infection, PLOS ONE, vol.11, issue.2, p.e0148452, 2016.

A. K. Wege, F. Weber, A. Kroemer, O. Ortmann, F. Nimmerjahn et al., IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM), Oncotarget, vol.8, issue.2, pp.2731-2744, 2016.

K. G. Elpek, M. P. Rubinstein, A. Bellemare-pelletier, A. W. Goldrath, and S. J. Turley, Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15R complexes, Proceedings of the National Academy of Sciences, vol.107, issue.50, pp.21647-21652, 2010.

J. Eisenman, M. Ahdieh, C. Beers, K. Brasel, M. K. Kennedy et al., INTERLEUKIN-15 INTERACTIONS WITH INTERLEUKIN-15 RECEPTOR COMPLEXES: CHARACTERIZATION AND SPECIES SPECIFICITY, Cytokine, vol.20, issue.3, pp.121-129, 2002.

J. K. Polansky, R. Bahri, M. Divivier, E. H. Duitman, C. Vock et al., High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner, Scientific Reports, vol.6, issue.1, 2016.

R. Tallerico, L. Conti, S. Lanzardo, R. Sottile, C. Garofalo et al., NK cells control breast cancer and related cancer stem cell hematological spread, OncoImmunology, vol.6, issue.3, p.e1284718, 2017.

A. López-soto, S. Gonzalez, M. J. Smyth, and L. Galluzzi, Control of Metastasis by NK Cells, Cancer Cell, vol.32, issue.2, pp.135-154, 2017.

T. A. Fehniger, K. Suzuki, J. B. Vandeusen, M. A. Cooper, A. G. Freud et al., Fatal Leukemia in Interleukin-15 Transgenic Mice, Blood Cells, Molecules, and Diseases, vol.27, issue.1, pp.223-230, 2001.

M. Frutoso, S. Morisseau, F. Tamzalit, A. Quéméner, D. Meghnem et al., Emergence of NK Cell Hyporesponsiveness after Two IL-15 Stimulation Cycles, The Journal of Immunology, vol.201, issue.2, pp.493-506, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-01805185

A. E. Maluish, J. R. Ortaldo, and R. B. Herberman, MODULATION OF NK ACTIVITY BY RECOMBINANT LEUKOCYTE INTERFERON IN ADVANCED CANCER PATIENTS, NK Cells and Other Natural Effector Cells, vol.131, pp.1279-1283, 1982.

F. Mattei, G. Schiavoni, F. Belardelli, and D. F. Tough, IL-15 Is Expressed by Dendritic Cells in Response to Type I IFN, Double-Stranded RNA, or Lipopolysaccharide and Promotes Dendritic Cell Activation, The Journal of Immunology, vol.167, issue.3, pp.1179-1187, 2001.

G. Romera-cárdenas, L. M. Thomas, S. Lopez-cobo, E. M. García-cuesta, E. O. Long et al., Ionomycin Treatment Renders NK Cells Hyporesponsive, PLOS ONE, vol.11, issue.3, p.e0150998, 2016.

S. L. Colpitts, T. A. Stoklasek, C. R. Plumlee, J. J. Obar, C. Guo et al., Cutting Edge: The Role of IFN-? Receptor and MyD88 Signaling in Induction of IL-15 Expression In Vivo, The Journal of Immunology, vol.188, issue.6, pp.2483-2487, 2012.

Q. Zhu, C. Egelston, S. Gagnon, Y. Sui, I. M. Belyakov et al., Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice, Journal of Clinical Investigation, vol.120, issue.2, pp.607-616, 2010.

S. Cooley, F. He, V. Bachanova, G. M. Vercellotti, T. E. Defor et al., First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia, Blood Advances, vol.3, issue.13, pp.1970-1980, 2019.

T. A. Waldmann, S. Dubois, M. D. Miljkovic, and K. C. Conlon, IL-15 in the Combination Immunotherapy of Cancer, Frontiers in Immunology, vol.11, p.868, 2020.

K. C. Conlon, E. L. Potter, S. Pittaluga, C. Lee, M. D. Miljkovic et al., IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion, Clinical Cancer Research, vol.25, issue.16, pp.4945-4954, 2019.

K. C. Conlon, E. Lugli, H. C. Welles, S. A. Rosenberg, A. T. Fojo et al., Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer, Journal of Clinical Oncology, vol.33, issue.1, pp.74-82, 2015.

T. O. Robinson and K. S. Schluns, The potential and promise of IL-15 in immuno-oncogenic therapies, Immunology Letters, vol.190, pp.159-168, 2017.

K. Margolin, C. Morishima, V. Velcheti, J. S. Miller, S. M. Lee et al., Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.24, issue.22, pp.5552-5561, 2018.

R. Romee, S. Cooley, M. M. Berrien-elliott, P. Westervelt, M. R. Verneris et al., First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation, Blood, vol.131, issue.23, pp.2515-2527, 2018.

J. A. Hangasky, T. A. Waldmann, and D. V. Santi, Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink, Frontiers in Immunology, vol.11, p.1813, 2020.

J. S. Miller, C. Morishima, D. G. Mcneel, M. R. Patel, H. E. Kohrt et al., A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors, Clinical Cancer Research, vol.24, issue.7, pp.1525-1535, 2017.

A. L. Ellis-connell, A. J. Balgeman, K. R. Zarbock, G. Barry, A. Weiler et al., ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment, Journal of Virology, vol.92, issue.3, p.1, 2017.

J. M. Wrangle, V. Velcheti, M. R. Patel, E. Garrett-mayer, E. G. Hill et al., ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial, The Lancet Oncology, vol.19, issue.5, pp.694-704, 2018.

M. Felices, A. J. Lenvik, R. Mcelmurry, S. Chu, P. Hinderlie et al., Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect, JCI Insight, vol.3, issue.3, 2018.

N. A. Hanick, M. Rickert, L. Varani, A. J. Bankovich, J. R. Cochran et al., Elucidation of the Interleukin-15 Binding Site on Its Alpha Receptor by NMR, Biochemistry, vol.46, issue.33, pp.9453-9461, 2007.

P. S. Kim, A. R. Kwilas, W. Xu, S. Alter, E. K. Jeng et al., Abstract 3245: IL-15 superagonist/IL-15R?Sushi-Fc fusion complex (IL-15SA/IL-15R?Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity of murine breast and colon carcinomas, Immunology, 2016.

P. S. Kim, A. R. Kwilas, W. Xu, S. Alter, E. K. Jeng et al., IL-15 superagonist/IL-15R?Sushi-Fc fusion complex (IL-15SA/IL-15R?Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas, Oncotarget, vol.7, issue.13, pp.16130-16145, 2016.

J. Chauvin, M. Ka, O. M. Pagliano, C. Menna, Q. Ding et al., IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma, Clinical Cancer Research, vol.26, issue.20, pp.5520-5533, 2020.

R. B. Delconte, T. B. Kolesnik, L. F. Dagley, J. Rautela, W. Shi et al., CIS is a potent checkpoint in NK cell?mediated tumor immunity, Nature Immunology, vol.17, issue.7, pp.816-824, 2016.

M. Zhang, W. Ju, Z. Yao, P. Yu, B. Wei et al., Augmented IL-15R? Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice, The Journal of Immunology, vol.188, issue.12, pp.6156-6164, 2012.

J. R. Van-audenaerde, E. Marcq, B. Scheidt, A. S. Davey, A. J. Oliver et al., Novel combination immunotherapy for pancreatic cancer: potent anti?tumor effects with CD40 agonist and interleukin?15 treatment, Clinical & Translational Immunology, vol.9, issue.8, p.1165, 2020.

S. Tognarelli, S. Wirsching, I. Von-metzler, B. Rais, B. Jacobs et al., Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma, Frontiers in Immunology, vol.9, p.2743, 2018.

P. F. Fiore, S. Di-matteo, N. Tumino, F. R. Mariotti, G. Pietra et al., Interleukin-15 and cancer: some solved and many unsolved questions, Journal for ImmunoTherapy of Cancer, vol.8, issue.2, p.e001428, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-03013809

M. Vincent, G. Teppaz, L. Lajoie, V. Solé, A. Bessard et al., Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse, mAbs, vol.6, issue.4, pp.1026-1037, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01680794

M. Vincent, A. Bessard, D. Cochonneau, G. Teppaz, V. Solé et al., Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency, International Journal of Cancer, vol.133, issue.3, pp.757-765, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02440732

P. R. Rhode, J. O. Egan, W. Xu, H. Hong, G. M. Webb et al., Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models, Cancer Immunology Research, vol.4, issue.1, pp.49-60, 2015.

M. Rosario, B. Liu, L. Kong, L. I. Collins, S. E. Schneider et al., The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas, Clinical Cancer Research, vol.22, issue.3, pp.596-608, 2015.

C. Jochems, S. R. Tritsch, K. M. Knudson, S. R. Gameiro, C. S. Rumfield et al., The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex, OncoImmunology, vol.8, issue.2, p.e1532764, 2018.

H. Furuya, O. T. Chan, I. Pagano, C. Zhu, N. Kim et al., Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model, Journal of Translational Medicine, vol.17, issue.1, p.29, 2019.

B. Liu, M. Jones, L. Kong, T. Noel, E. K. Jeng et al., Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models, Cytokine, vol.107, pp.105-112, 2018.

P. S. Kim, A. R. Kwilas, W. Xu, S. Alter, E. K. Jeng et al., Abstract 3245: IL-15 superagonist/IL-15R?Sushi-Fc fusion complex (IL-15SA/IL-15R?Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity of murine breast and colon carcinomas, Immunology, 2016.

P. S. Kim, A. R. Kwilas, W. Xu, S. Alter, E. K. Jeng et al., IL-15 superagonist/IL-15R?Sushi-Fc fusion complex (IL-15SA/IL-15R?Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas, Oncotarget, vol.7, issue.13, pp.16130-16145, 2016.

D. Mathios, C. K. Park, W. D. Marcus, S. Alter, P. R. Rhode et al., Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model, International Journal of Cancer, vol.138, issue.1, pp.187-194, 2015.

W. Xu, M. Jones, B. Liu, X. Zhu, C. B. Johnson et al., Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma, Cancer Research, vol.73, issue.10, pp.3075-3086, 2013.

M. Rosario, B. Liu, L. Kong, L. I. Collins, S. E. Schneider et al., The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas, Clinical Cancer Research, vol.22, issue.3, pp.596-608, 2015.

E. Moga, E. Cantó, S. Vidal, C. Juarez, J. Sierra et al., Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression, Experimental Hematology, vol.39, issue.11, pp.1064-1071, 2011.

B. Liu, L. Kong, K. Han, H. Hong, W. D. Marcus et al., A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses, Journal of Biological Chemistry, vol.291, issue.46, pp.23869-23881, 2016.

M. Zhang, B. Wen, O. M. Anton, Z. Yao, S. Dubois et al., IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages, Proceedings of the National Academy of Sciences, vol.115, issue.46, pp.E10915-E10924, 2018.

S. Dubois, H. J. Patel, M. Zhang, T. A. Waldmann, and J. R. Müller, Preassociation of IL-15 with IL-15R?-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action, The Journal of Immunology, vol.180, issue.4, pp.2099-2106, 2008.

M. Zhang, W. Ju, Z. Yao, P. Yu, B. R. Wei et al., Augmented IL-15R? Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice, The Journal of Immunology, vol.188, issue.12, pp.6156-6164, 2012.

P. Yu, J. C. Steel, M. Zhang, J. C. Morris, R. Waitz et al., Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model, Proceedings of the National Academy of Sciences, vol.109, issue.16, pp.6187-6192, 2012.

M. Zhao, M. Luo, Y. Xie, H. Jiang, C. Cagliero et al., Development of a recombinant human IL-15·sIL-15R?/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model, Biomedicine & Pharmacotherapy, vol.112, p.108677, 2019.

K. M. Knudson, K. C. Hicks, S. Alter, J. Schlom, and S. R. Gameiro, Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy, Journal for ImmunoTherapy of Cancer, vol.7, issue.1, p.82, 2019.

K. M. Knudson, K. C. Hicks, Y. Ozawa, J. Schlom, and S. R. Gameiro, Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist, Journal for ImmunoTherapy of Cancer, vol.8, issue.1, p.e000493, 2020.